Semax for stroke recovery: what the research actually shows.

Russian hospitals have administered Semax in acute stroke care for over two decades. No Western Phase III has replicated the data, and a single rat lab is doing most of the legwork to explain why.

Of every peptide we cover, Semax has the most clinically credible Russian use case. Stroke is a neurological emergency with a tight therapeutic window. Russian hospitals have used Semax in stroke care for over 20 years, alongside clot-busting drugs, with reports of smaller infarct size and better recovery.

What's missing is Western validation. No major U.S. or European group has run a confirmatory trial. The Kurchatov Institute group in Moscow has done genuinely rigorous preclinical work, but the leap from "consistent rat data" to "FDA-approved stroke drug" hasn't happened.

This article walks through the rat data, the Russian clinical use, and the structural reasons no Western lab has stepped up.

What does the Kurchatov Institute work show?

The Limborska, Dergunova, and Filippenkov group in Moscow has published the deepest preclinical record any peptide in our library has. Their work uses tMCAO — transient middle cerebral artery occlusion. That's a standard rat surgery that mimics an ischemic stroke: clamp a brain artery for 90 to 120 minutes, then let blood flow back. The result is a localized stroke in the cortex with motor and cognitive deficits you can measure.

Here's what their RNA-seq studies have found:

• Inflammation drops at 4.5 hours. The 2021 Dergunova paper showed Semax suppresses the inflammatory cytokine mRNAs (IL-1α, IL-1β, IL-6, CCL3, CXCL2) that spike when blood floods back into damaged tissue. The 4.5-hour timepoint matters because that's still inside the clinical treatment window.
• Key proteins shift at 24 hours. The 2021 Sudarkina paper tracked changes in CREB (brain plasticity), MMP-9 (tissue remodeling), c-Fos (the cell's early-warning system), and JNK (inflammation/cell-death signaling).
• The immune response normalizes, not silences. The 2023 Filippenkov paper showed Semax tunes the immune response toward controlled resolution, not blanket suppression.
• Over a thousand genes rebalance at 24 hours. The 2024 Filippenkov paper found Semax shifts 1,171 stroke-disrupted genes back toward baseline.

The methodology is solid. Multi-timepoint RNA-seq, consistent across papers, with a clear biological narrative. This is the kind of preclinical record that would typically support an IND filing for a Phase II neuroprotection trial.

What about motor recovery?

The transcriptomics tells you what's happening to genes. Motor-recovery studies tell you whether the rat actually walks better. The most consequential recent functional study isn't even about stroke.

The Liu 2025 paper in British Journal of Pharmacology tested Semax in mouse spinal cord injury. Mice recovered function faster when treated with Semax. The mechanism was new: Semax engaged the μ-opioid receptor (the same receptor morphine binds, but used here in a non-painkilling way) to drive a pathway involving USP18 and FTO, two proteins that regulate how cells dispose of damaged inflammatory machinery.

Spinal cord injury isn't stroke, but the bigger point is what makes this paper consequential. BJP is a selective journal. The methodology is rigorous. The authors have no ties to the Russian developers. This is the strongest independent confirmation Semax has gotten in years.

The Inozemtseva 2024 study in European Journal of Pharmacology tested Semax at 60 nmol/kg/day in a chronic stress model, not stroke. The relevance is partial: the BDNF pathway it engages overlaps with what post-stroke cognitive recovery uses, but the model isn't stroke itself.

Semax

ACTH(4-10) analog 7 aa N-acetylated

The same Russian-school neuroprotective peptide cited across the stroke-model preclinical literature in this article. Lab-verified identity and purity.

View Semax

Why nasal drops, not injections?

Russian hospitals give Semax exclusively as nasal drops — first dose in the ER, then continued through early recovery. The route isn't a quirk. It's deliberate.

Subcutaneous or IV routes deliver the peptide into systemic circulation first, where peptidases (enzymes that cleave peptides) can degrade a significant fraction before any reaches the brain. The nasal mucosa offers a different pathway: a portion of an intranasally administered peptide can travel directly into brain tissue via the olfactory and trigeminal nerves, partially bypassing the blood-brain barrier (BBB).

This pharmacokinetic distinction is relevant to the acute stroke context, where the neuroprotective window is measured in hours. Faster CNS delivery has been proposed as an advantage for time-sensitive interventions.

Semax's structural design supports this delivery route. Native ACTH(4-7), the parent fragment, is degraded too rapidly by nasal-lining peptidases to achieve meaningful CNS exposure. Semax incorporates a C-terminal Pro-Gly-Pro stability tail that confers sufficient enzymatic resistance to survive transit across the nasal mucosa — the design feature that makes intranasal delivery viable.

What does the Russian clinical experience claim?

Russian-language literature over the past two decades reports four outcomes: smaller final infarct size, better recovery scores on motor and functional assessments, less post-stroke cognitive impairment, and a favorable safety profile. The administration route used in these reports was intranasal nasal drops, initiated acutely and continued through the recovery window.

By Western standards, none of this is Phase III data. The trials predate trial registration. They're published in Russian-language journals not indexed in PubMed. The investigators overlap with the molecule's developers. Blinding, randomization, and outcome specification don't consistently meet modern rigor.

Same framing as Selank: the Russian work is real but not interchangeable with a registered Western Phase III. It supports prescribing inside Russia. It doesn't, on its own, support Western use.

Why hasn't anyone run a Western trial?

Three reasons.

The neuroprotection field is brutal. Only two acute-stroke interventions are FDA-approved: tPA (clot-busting drugs) and mechanical thrombectomy (pulling the clot out). Both work by restoring blood flow, not protecting brain tissue. The neuroprotection subfield has produced over 1,000 Phase III failures. New candidates face an extraordinarily high bar.

The economics don't work. Semax's IP belongs to Russian institutions. The molecule is effectively off-patent. A Phase III acute-stroke trial runs $50–200 million over multiple years with complex acute-care infrastructure. No commercial sponsor has reason to fund it.

Western academia doesn't trust unreplicated Russian work. The Kurchatov data is high quality, but it's concentrated in one lab with overlapping authorship. Western grant committees won't fund a Phase III without independent preclinical confirmation. The 2025 BJP paper is the first significant independent replication — non-Russian, top-tier journal, rigorous method. More of that could shift the field.

What about post-stroke cognitive recovery?

About one in three stroke survivors develops persistent cognitive impairment, and almost nothing on the FDA-approved list targets it directly. Russian clinical use of Semax explicitly includes this indication, which is arguably the strongest framing for the molecule.

The mechanistic logic holds together. Semax upregulates BDNF and NGF (growth factors brain repair relies on), shifts synaptic-function pathways in the 2024 transcriptomics work, modulates CREB (a master regulator of memory and plasticity), and tamps down post-stroke inflammation. Every one of those touches a pathway that matters for cognitive recovery.

The Italian copper-chelation work by Sciacca (2022) adds an Alzheimer's-adjacent angle: Semax binds copper ions, prevents copper-amyloid complexes from forming, and reduces oxidative damage those complexes drive. Relevant any time copper dysregulation contributes to brain decline.

None of this constitutes Phase III evidence for post-stroke cognitive impairment. Collectively, the data represent a coherent mechanistic hypothesis supported by Russian clinical experience — a foundation that would need confirmatory Western trial data before the indication could be considered established.

Semax

11 mg ≥99% pure Lyophilized

ACTH(4-10) analog · 7 aa, N-acetylated. The same reference compound used across the cited preclinical studies. COA available with each lot.

Learn more

Research gaps and clinical context

Several open questions remain relevant to interpreting the Semax stroke literature:

• Standard-of-care anchoring. tPA, mechanical thrombectomy, anticoagulation, statins, blood pressure control, and structured rehabilitation represent the evidence-based standard. Preclinical and Russian clinical Semax data have not been evaluated alongside these interventions in a controlled Western trial.
• Preclinical-to-clinical translation. The Kurchatov transcriptomics record and the 2025 BJP spinal cord paper represent the strongest available evidence base, yet neither has been followed by a registered Phase II or III stroke trial in the West.
• Therapeutic window dependence. Semax's preclinical signal is concentrated in the first hours and days post-ischemia. The mechanism is considerably less supported in the chronic post-stroke phase.
• Route-of-administration pharmacokinetics. The Russian clinical literature describes intranasal nasal drops. Subcutaneous administration produces a different pharmacokinetic profile and has not been studied in stroke models.
• Novel receptor findings. The 2025 μ-opioid receptor / USP18 / FTO finding raises pharmacological interaction questions with opioid medications, antiplatelets, anticoagulants, and other neuroactive agents that have not been systematically investigated.
• Product heterogeneity. Russian pharmaceutical-grade intranasal Semax and research-peptide preparations may differ in formulation, purity, and excipients — these are not equivalent in a pharmacological sense.